

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)



(10) International Publication Number
WO 2021/205298 A1

(51) International Patent Classification:

C07F 9/6558 (2006.01) *A61P 31/14* (2006.01)
A61K 31/662 (2006.01)

(21) International Application Number:

PCT/IB2021/052741

(22) International Filing Date:

01 April 2021 (01.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/005,407	05 April 2020 (05.04.2020)	US
63/038,454	12 June 2020 (12.06.2020)	US
63/061,628	05 August 2020 (05.08.2020)	US
63/065,658	14 August 2020 (14.08.2020)	US
63/073,145	01 September 2020 (01.09.2020)	US
63/114,289	16 November 2020 (16.11.2020)	US
63/163,635	19 March 2021 (19.03.2021)	US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **BEZAWADA, Padmavani**; c/o Pfizer Inc.,
275 N. Field Drive, Lake Forest, Illinois 60045 (US).
HAWKING, Emma Louise; c/o Pfizer R&D UK Limited,
Ramsgate Road, Sandwich Kent CT 13 9NJ, England (GB).

HOFFMAN, Robert Louis; c/o Pfizer Inc., 10777 Science
Center Drive, San Diego, California 92121 (US). **JAINI,
Rohit**; c/o Pfizer Inc., 275 N. Field Drive, Lake Forest,
Illinois 60045 (US). **KANIA, Robert Steven**; 13796 No-
gales Drive, Del Mar, California 92014 (US). **KULKARNI,
Samir**; c/o Pfizer Inc., 445 Eastern Point Road, Building
98, Groton, Connecticut 06340 (US). **LILLIS, Jonathan
Richard**; c/o Pfizer R&D UK Limited, Ramsgate Road,
Sandwich Kent CT 13 9NJ, England (GB). **LUTHRA,
Suman**; 6 Cutter Lane, Westford, Massachusetts 01886
(US). **O'BRIEN LARAMY, Matthew Nathan**; c/o Pfizer
Inc., 275 N. Field Drive, Lake Forest, Illinois 60045
(US). **OWEN, Dafydd Rhys**; c/o Pfizer Inc., 610 Main
Street, Cambridge, Massachusetts 02139 (US). **PENCHE-
VA, Klimentina Dimitrova**; c/o Pfizer R&D UK Limited,
Ramsgate Road, Sandwich Kent CT 13 9NJ, England (GB).
PETTERSSON, Martin Youngjin; 3 Gilson Road, Little-
ton, Massachusetts 01460 (US). **RANE, Anil Mahadeo**; c/
o Pfizer Inc., 445 Eastern Point Road, Building 98, Gro-
ton, Connecticut 06340 (US). **SAMMONS, Matthew For-
rest**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massa-
chusetts 02139 (US). **SULLIVAN, Bradley Paul**; c/o Pfizer
Inc., 275 N. Field Drive, Lake Forest, Illinois 60045 (US).
THIEL, Andrew John; c/o Pfizer Inc., 275 N. Field Drive,
Lake Forest, Illinois 60045 (US). **TICEHURST, Martyn
David**; c/o Pfizer R&D UK Limited, Ramsgate Road, Sand-

(54) Title: COMPOUNDS AND METHODS FOR THE TREATMENT OF COVID-19

(57) Abstract: The invention relates to compounds of formula I wherein R^1 , R^2 and ---- are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.




FIG. 1



WO 2021/205298 A1

[Continued on next page]

wich Kent CT 13 9NJ, England (GB). **TUTTLE, Jamison Bryce**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US).

(74) **Agent: ZIELINSKI, Bryan C.**; PFIZER INC., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*